Skip to main content
    J

    Jazz Pharmaceuticals PLC (JAZZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $240.71
    +0.94 (+0.39%)

    Market Cap: $15.39B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Jazz Pharmaceuticals PLC (JAZZ) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Jazz Pharmaceuticals (JAZZ) has a market cap of $15.39B and an enterprise value of $18.92B. Its share count is up 6.59% from a year earlier. Its trailing P/E of 18.5x is above its 10-year median of 10.0x.

    Total Valuation

    Enterprise value is 22.96% above the market cap, as debt exceeds cash.

    Market Cap$15.39B
    Enterprise Value$18.92B
    Latest price (Nov 17, 2026)$240.71

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 2, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.37% in the quarter ended Sep 30, 2026 and grew 2.64% a year over 2 years.

    Shares Outstanding64.70M
    Shares Change (YoY)+6.59%
    Shares Change (QoQ)+2.37%
    Share Count Growth (2Y CAGR)+2.64%

    Valuation Ratios

    Sales and book value multiples are 3.3x and 3.7x. Its year-end P/E ranged from 5.8x to 24.1x from 2016 to 2025.

    P/E Ratio18.5x
    Forward P/E15.8x
    P/S Ratio3.3x
    Forward P/S3.2x
    P/B Ratio3.7x
    P/FCF Ratio21.8x
    P/OCF Ratio9.1x
    PEG Ratio0.6

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 16.7x EBITDA and 26.8x free cash flow.

    EV / Earnings91.9x
    EV / Sales4.0x
    EV / EBITDA16.7x
    EV / EBIT44.2x
    EV / FCF26.8x

    Price Statistics

    The stock is up 70.63% over 52 weeks and trades 5.11% above its 50-day average.

    Beta (1Y)0.70
    52-Week Change+70.63%
    1-Month Change+15.49%
    3-Month Change-4.54%
    6-Month Change+1.37%
    5-Year Change+62.34%
    10-Year Change+97.30%
    Total Return (1Y)+70.63%
    Total Return (3Y CAGR)+25.91%
    Total Return (5Y CAGR)+13.07%
    Return vs SPY (1Y)+21.78%
    Max Drawdown (1Y)-21.62%
    Max Drawdown (3Y)-32.18%
    Sharpe Ratio (1Y)0.91
    Correlation with SPY (1Y)0.30
    50-Day Average$229.00
    200-Day Average$220.77
    52-Week Range$156.95 to $266.38
    RSI (14 Days)59.7
    Average Volume (20 Days)786.47K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.82x current liabilities, and total debt is 1.33x shareholder equity.

    Current Ratio1.82x
    Quick Ratio1.64x
    Debt / Equity1.33x
    Debt / EBITDA4.86x
    Debt / FCF7.80x

    Returns and Efficiency

    Return on invested capital is 3.48% over the last 12 months, against a 5-year average of 2.26%.

    Return on Equity (ROE)4.91%
    Return on Assets (ROA)1.72%
    Return on Invested Capital (ROIC)3.48%
    Return on Capital Employed (ROCE)4.52%
    ROE (5Y Average)0.19%
    ROA (5Y Average)0.10%
    ROIC (5Y Average)2.26%
    Asset Turnover0.40x
    Inventory Turnover1.15x
    Receivables Turnover5.38x
    Cash Conversion Cycle206 days

    Taxes

    Income tax took 20.66% of pretax income over the last 12 months.

    Income Tax (TTM)$53.66M
    Effective Tax Rate20.66%

    Scores

    JAZZ has an Altman Z-Score of 1.97, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score1.97
    Altman Z ZoneGrey
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $4.72B over the last 12 months is up 13.48% from the 12 months before.

    Revenue$4.72B
    Revenue Growth (YoY)+13.48%
    Gross Profit$4.20B
    Operating Income$425.94M
    Pretax Income$259.77M
    Net Income$205.95M
    EBITDA$1.15B
    EBIT$427.68M
    Reported EPS (TTM)$13.04

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 34.92% of the $12.00B in total assets.

    Cash and Equivalents$2.04B
    Total Debt$5.57B
    Net Debt$3.53B
    Net Debt Per Share$54.61
    Working Capital$2.08B
    Shareholder Equity$4.19B
    Book Value Per Share$64.79
    Tangible Book Value-$1.78B
    Total Assets$12.00B
    Total Liabilities$7.81B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $978.73M of capital spending, operating cash flow left $713.79M of free cash flow.

    Operating Cash Flow$1.69B
    Capital Expenditures$978.73M
    Free Cash Flow$713.79M
    FCF Per Share$11.00
    Depreciation and Amortization$718.57M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 9.03%, against a 5-year average of 5.27%.

    Gross Margin89.09%
    Operating Margin9.03%
    Pretax Margin5.51%
    Net Margin4.37%
    EBITDA Margin24.29%
    EBIT Margin9.06%
    FCF Margin15.13%
    Gross Margin (5Y Average)87.38%
    Operating Margin (5Y Average)5.27%
    Net Margin (5Y Average)-0.11%

    Growth

    Revenue grew 5.26% a year over 3 years, and EPS fell 18.68% a year.

    Revenue Growth (3Y CAGR)+5.26%
    Revenue Growth (5Y CAGR)+12.54%
    EPS Growth (3Y CAGR)-18.68%
    EPS Growth (5Y CAGR)-10.75%
    FCF Growth (3Y CAGR)-29.31%
    FCF Growth (5Y CAGR)-13.08%
    Book Value Per Share Growth (2Y CAGR)+14.90%

    Revenue and profit by year

    Dividends and Yields

    JAZZ does not pay a dividend. Its free cash flow yield is 4.58%.

    Earnings Yield5.41%
    FCF Yield4.58%
    Buyback Yield0.47%
    Shareholder Yield0.47%

    Peer Position

    Against 4 similar companies, JAZZ has the 3rd highest P/E.

    P/E Ratio18.5x vs 18.7x median
    P/S Ratio3.3x vs 11.7x median
    ROIC3.48% vs -2.58% median
    Revenue Growth (Trailing 4 Quarters, YoY)+13.48% vs +68.56% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 8.95% and EPS growth at 94.52% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+8.95%
    EPS Growth Forecast (2Y CAGR)+94.52%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About JAZZ

    What is JAZZ's market cap?

    Jazz Pharmaceuticals has a market cap of $15.39B. Its enterprise value, which adds debt and subtracts cash, is $18.92B.

    What is JAZZ's P/E ratio?

    Jazz Pharmaceuticals has a trailing P/E ratio of 18.5x and a forward P/E of 15.8x.

    How many shares of JAZZ are outstanding?

    Jazz Pharmaceuticals has 64.70M shares outstanding. The count is up 6.59% from a year earlier.

    Does JAZZ pay a dividend?

    No. Jazz Pharmaceuticals does not pay a dividend.

    How much debt does JAZZ have?

    Jazz Pharmaceuticals has $5.57B of total debt and $2.04B of cash and equivalents, a net debt position of $3.53B.